Sibylle Loibl, MD, PhD, of the German Breast Group, discusses results from the phase III GeparNUEVO study, which investigated neoadjuvant durvalumab in addition to anthracycline/taxane-based neoadjuvant chemotherapy in patients with early triple-negative breast cancer (Abstract 506).
Neeraj Agarwal, MD, of Huntsman Cancer Institute at the University of Utah, discusses three studies that examined real-world treatment patterns and utilization of advanced therapies in men with metastatic castration-sensitive prostate cancer, which served to highlight the ways in which Black men may be treated differently (Abstracts 5072, 5073, 5704).
Brian K. Link, MD, of the University of Iowa Carver College of Medicine, reviews three abstracts on state-of-the-art therapies for mantle cell lymphoma: bendamustine, rituximab, lenalidomide and bortezomib; treatment patterns and outcomes for previously untreated patients; and venetoclax, lenalidomide, and rituximab in newly diagnosed disease (Abstracts 7503, 7504, and 7505).
Karim Fizazi, MD, PhD, of Institut Gustave Roussy, discusses first results from the phase III PEACE1 trial, which showed that abiraterone plus androgen-deprivation therapy and docetaxel improves radiographic progression-free survival in men with de novo metastatic prostate cancer (Abstract 5000).
Priya Rastogi, MD, of the University of Pittsburgh, discusses results from the NRG Oncology/NSABP B-42 trial, which evaluated the utility of the 70-gene MammaPrint assay in predicting the benefit of extended letrozole therapy in patients who had completed 5 years of adjuvant endocrine therapy (Abstract 502).
Paolo Ghia, MD, PhD, of the Università Vita-Salute San Raffaele, discusses phase II results from the CAPTIVATE study, which examined ibrutinib plus venetoclax as a fixed-duration first-line treatment in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (Abstract 7501).
